Trial Profile
A Phase 3, Open-Label, Randomized, Active-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib Versus Gemcitabine Plus Cisplatin Chemotherapy in First-Line Treatment of Participants With Unresectable or Metastatic Cholangiocarcinoma With FGFR2 Rearrangement (FIGHT-302)
Status:
Recruiting
Phase of Trial:
Phase III
Latest Information Update: 18 Mar 2024
Price :
$35
*
At a glance
- Drugs Pemigatinib (Primary) ; Cisplatin; Gemcitabine
- Indications Cholangiocarcinoma
- Focus Registrational; Therapeutic Use
- Acronyms FIGHT-302
- Sponsors Incyte Corporation
- 17 Oct 2022 Planned End Date changed from 18 Feb 2028 to 27 Jul 2028.
- 17 Oct 2022 Planned primary completion date changed from 20 Mar 2027 to 26 Oct 2027.
- 16 Feb 2022 Planned number of patients changed from 432 to 434.